Eventus Bio

Eventus Bio is a preclinical-stage biotechnology company developing next-generation AAV-based gene therapies for neurodegenerative diseases. The company utilizes a proprietary silence and replace platform, which is designed to simultaneously knock down a disease-causing mutant gene and deliver a functional copy of the gene to restore normal protein function. Co-founded by Dr. Guangping Gao, a pioneer in AAV vector engineering, and Dr. Dan Wang, the company's lead program targets SOD1-associated amyotrophic lateral sclerosis (ALS). Eventus Bio aims to leverage its advanced viral vector technology to create durable, one-time treatments for patients with devastating genetic conditions.